Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece.
OBJECTIVE
To report our preliminary experience in the combined treatment of peritoneal carcinomatosis (PC) using cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).


METHODS
This prospective study included patients with PC from gynaecological, gastric and colon cancer, treated in two centers. Cytoreductive surgery included the peritonectomy procedures described by Jacquet and Sugarbaker as well as multivisceral resections in order to achieve a complete macroscopical cancer eradication. The HIPEC that followed was performed via the open abdomen technique.


RESULTS
Twenty-four patients (3 men and 21 women, mean age 60 years) were treated. Twelve patients had PC from ovarian cancer, 7 from colon, 3 from gastric and 2 from uterine cancer. The mean duration of the procedure was 7.83 h (range 5 -12.30). Macroscopically, complete cytoreduction (CC) was achieved in 18 (75%) patients. Two (8.3%) patients died in the first 30 days. The overall morbidity was 42% and 2 patients were reoperated. The mean follow up was 22 months (range 3-36). The overall 1-year survival was 59.1%; concerning the gynaecological cancers it was 53.8% (mean survival 11.7 months) and for gastrointestinal cancers it was 44.4% (mean survival 9.5 months).


CONCLUSIONS
Our preliminary data suggest that the combined treatment of cytoreduction plus HIPEC for PC is associated with acceptable mortality and morbidity and offers an improved survival in these patients. An optimal patient selection and establishment of experienced centres are of paramount importance.
Spiliotis
J
J
Department of Surgery, Messologi General Hospital, Messologi, Greece. jspil@in.gr
Tentes
A A K
AA
Vaxevanidou
A
A
Korakianitis
O S
OS
Rogdakis
A
A
Mirelis
C G
CG
Datsis
A C
AC
Kekelos
S
S
D000328:Adult; D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000191:economics / Q000473:pathology / Q000601:surgery / Q000628:therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000191:economics / Q000473:pathology / Q000601:surgery / Q000628:therapy; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000191:economics / Q000473:pathology / Q000601:surgery / Q000628:therapy; D015996:Survival Rate; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000191:economics / Q000473:pathology / Q000601:surgery / Q000628:therapy